Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 49

1.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

PMID:
23602817
[PubMed - indexed for MEDLINE]
2.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
[PubMed - indexed for MEDLINE]
3.

[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].

Hunyady B, Kovács B, Battyáni Z.

Orv Hetil. 2011 Dec 11;152(50):1997-2009. doi: 10.1556/OH.2011.29266. Review. Hungarian.

PMID:
22112373
[PubMed - indexed for MEDLINE]
4.

Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.

Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM.

Can J Gastroenterol. 2012 Apr;26(4):205-10. Review.

PMID:
22506260
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.

Ferenci P, Reddy KR.

Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934. Review.

PMID:
22155901
[PubMed - indexed for MEDLINE]
6.

[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].

Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S.

Z Gastroenterol. 2012 Jan;50(1):57-72. doi: 10.1055/s-0031-1282015. Epub 2012 Jan 5. Review. German.

PMID:
22222799
[PubMed - indexed for MEDLINE]
7.

Boceprevir: a protease inhibitor for the treatment of hepatitis C.

Chang MH, Gordon LA, Fung HB.

Clin Ther. 2012 Oct;34(10):2021-38. doi: 10.1016/j.clinthera.2012.08.009. Epub 2012 Sep 11. Review.

PMID:
22975763
[PubMed - indexed for MEDLINE]
8.

Telaprevir: a hepatitis C NS3/4A protease inhibitor.

Matthews SJ, Lancaster JW.

Clin Ther. 2012 Sep;34(9):1857-82. doi: 10.1016/j.clinthera.2012.07.011. Epub 2012 Aug 28. Review.

PMID:
22951253
[PubMed - indexed for MEDLINE]
9.

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

Shiffman ML, Esteban R.

Liver Int. 2012 Feb;32 Suppl 1:54-60. doi: 10.1111/j.1478-3231.2011.02718.x. Review.

PMID:
22212573
[PubMed - indexed for MEDLINE]
10.

Future perspectives: towards interferon-free regimens for HCV.

Gane E.

Antivir Ther. 2012;17(6 Pt B):1201-10. doi: 10.3851/IMP2431. Epub 2012 Oct 5. Review.

PMID:
23186654
[PubMed - indexed for MEDLINE]
11.

Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.

Garnock-Jones KP.

Drugs. 2012 Dec 24;72(18):2431-56. doi: 10.2165/11209560-000000000-00000. Review.

PMID:
23231027
[PubMed - indexed for MEDLINE]
12.

Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review.

Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R.

Ann Intern Med. 2013 Jan 15;158(2):114-23. Review.

PMID:
23437439
[PubMed - indexed for MEDLINE]
13.

Telaprevir: changing the standard of care of chronic hepatitis C.

Rajani AK, Ravindra BK, Dkhar SA.

J Postgrad Med. 2013 Jan-Mar;59(1):42-7. doi: 10.4103/0022-3859.109493. Review.

PMID:
23525057
[PubMed - indexed for MEDLINE]
Free Article
14.

Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.

Tungol A, Rademacher K, Schafer JA.

J Manag Care Pharm. 2011 Nov;17(9):685-94. Review.

PMID:
22050393
[PubMed - indexed for MEDLINE]
Free Article
15.

Telaprevir for the treatment of chronic hepatitis C infection.

Muir AJ.

Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105-14. doi: 10.1586/eri.11.133. Review.

PMID:
22114960
[PubMed - indexed for MEDLINE]
16.

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.

Swiss Association for the Study of the Liver.

Swiss Med Wkly. 2012 Feb 24;142:w13516. doi: 10.4414/smw.2012.13516. Review.

PMID:
22367957
[PubMed - indexed for MEDLINE]
Free Article
17.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
[PubMed - indexed for MEDLINE]
18.

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.

Barritt AS 4th, Fried MW.

Gastroenterology. 2012 May;142(6):1314-1323.e1. doi: 10.1053/j.gastro.2012.02.013. Review.

PMID:
22537438
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.

Esteban R, Buti M.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):445-53. doi: 10.1016/j.bpg.2012.09.001. Review.

PMID:
23199503
[PubMed - indexed for MEDLINE]
20.

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.

Pearlman BL.

Lancet Infect Dis. 2012 Sep;12(9):717-28. doi: 10.1016/S1473-3099(12)70060-9. Epub 2012 May 29. Review.

PMID:
22647717
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk